Free Trial

Pfizer (PFE) Stock Price, News & Analysis

Pfizer logo
$25.33 +1.48 (+6.21%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pfizer Stock (NYSE:PFE)

Advanced

Key Stats

Today's Range
$23.81
$25.41
50-Day Range
$23.27
$25.83
52-Week Range
$20.92
$30.43
Volume
124.02 million shs
Average Volume
45.68 million shs
Market Capitalization
$144.02 billion
P/E Ratio
13.47
Dividend Yield
6.79%
Price Target
$28.12
Consensus Rating
Hold

Company Overview

Pfizer Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

PFE MarketRank™: 

Pfizer scored higher than 98% of companies evaluated by MarketBeat, and ranked 6th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 4 buy ratings, 11 hold ratings, and 1 sell rating.

  • Upside Potential

    Pfizer has a consensus price target of $28.12, representing about 11.4% upside from its current price of $25.24.

  • Amount of Analyst Coverage

    Pfizer has only been the subject of 3 research reports in the past 90 days.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to grow by 2.71% in the coming year, from $2.95 to $3.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is 13.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.49.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is 13.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.96.

  • Price to Earnings Growth Ratio

    Pfizer has a PEG Ratio of 0.77. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pfizer's valuation and earnings.
  • Percentage of Shares Shorted

    1.99% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 9.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 7.29%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 16 years.

  • Dividend Coverage

    The dividend payout ratio of Pfizer is 91.49%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 56.77% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • Percentage of Shares Shorted

    1.99% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 9.14%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pfizer has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 118 news articles for Pfizer this week, compared to 71 articles on an average week.
  • Search Interest

    321 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • MarketBeat Follows

    88 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 69% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Stock News Headlines

President Donald Trump speaks in the Oval Office of the White House, Tuesday, Sept
Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump
Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with President Donald Trump's administration...
People pass the New York Stock Exchange on November 5, 2024, in New York
Asian shares trade mostly higher after Wall Street snaps its 3-day losing streak
Shares are mostly higher in Asia after Wall Street broke its three-day losing streak, trimming its losses for the week...
Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
Pfizer Building
Pfizer is Locking in New Growth Through a New Acquisition
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.
A currency trader passes by a screen showing the Korea Composite Stock Price Index…
Asian shares trade mixed after US stocks set more records
Asian shares are trading mixed in the absence of key market-driving news in the region, after a seemingly relentless rally continued on Wall Street...
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $26.53 at the beginning of 2025. Since then, PFE stock has decreased by 4.9% and is now trading at $25.2390.

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, August, 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company's quarterly revenue was up 10.3% compared to the same quarter last year.
Read the conference call transcript
.

Pfizer subsidiaries include these companies: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and more.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol Myers Squibb (BMY).

Company Calendar

Record date for 9/2 Dividend
7/25/2025
Ex-Dividend for 9/2 Dividend
7/25/2025
Last Earnings
8/05/2025
Dividend Payable
9/02/2025
Today
9/30/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:PFE
CIK
78003
Employees
81,000
Year Founded
1849

Price Target and Rating

High Price Target
$33.00
Low Price Target
$23.00
Potential Upside/Downside
+17.9%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.88
Trailing P/E Ratio
12.68
Forward P/E Ratio
8.08
P/E Growth
0.77
Net Income
$8.03 billion
Net Margins
16.84%
Pretax Margin
16.50%
Return on Equity
21.42%
Return on Assets
9.12%

Debt

Debt-to-Equity Ratio
0.65
Current Ratio
1.16
Quick Ratio
0.85

Sales & Book Value

Annual Sales
$63.83 billion
Price / Sales
2.12
Cash Flow
$4.38 per share
Price / Cash Flow
5.44
Book Value
$15.62 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
5,685,551,000
Free Float
5,682,140,000
Market Cap
$135.54 billion
Optionable
Optionable
Beta
0.55

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:PFE) was last updated on 9/30/2025 by MarketBeat.com Staff
From Our Partners